ImmunityBio announced results from two analyses comparing its bladder cancer treatment, ANKTIVA (NAI) plus BCG, against two FDA-approved therapies. Researchers presented the data at the 2026 American Urological Association Annual Meeting.
Patients using NAI+BCG were twice as likely to achieve a complete response compared to those receiving nadofaragene firadenovec-vncg. The median duration of complete response for NAI+BCG was 22.1 months. This duration more than doubled the 9.7 months recorded for nadofaragene. The combination therapy reduced the risk of cystectomy by 60%.
Compared to TAR-200, NAI+BCG showed numerically higher 12-month complete response rates. The treatment also showed a statistically significant reduction in treatment-related adverse events versus TAR-200.